Continuous Bioprocessing Market Growth

Continuous bioprocessing market growth is anticipated at a CAGR of 10% till 2035

 

The surge in demand for COVID-19 vaccines has presented lucrative opportunities for both innovators and contract service providers having continuous and semi-continuous manufacturing capabilities for biointensification

Roots Analysis has announced the addition of Continuous Bioprocessing Market report to its list of offerings.

Given the growing pipeline of biological drugs, and the rising preference for such therapeutic interventions, the demand for cost-effective biomanufacturing processes has increased. As a result, several innovators and contract service providers are evaluating the potential of continuous and semi-continuous upstream and downstream bioprocessing technologies, owing to their various advantages.

To order this 190+ page report, which features 60+ figures and 115+ tables, please visit https://www.rootsanalysis.com/reports/continuous-and-semi-continuous-bioprocessing-market.html

Key Market Insights

Presently, more than 70 companies claim to have capabilities for continuous manufacturing of biologics
Close to 45% of the continuous and semi-continuous bioprocessing companies are headquartered in Europe; further, around 20% of these companies have established their dedicated facilities in other geographical regions, such as North America and Asia-Pacific.

Over 65% of the installed continuous upstream manufacturing capacity belongs to established players
More than 40% of the global continuous upstream processing capacity is installed in Europe, followed by Asia-Pacific (33%). Further, close to 55% of the capacity belongs to the facilities owned by contract service providers.

Continuous and semi-continuous bio-intensification approach has potential to save ~40% of the overall biopharmaceutical manufacturing cost
By 2030, we expect that adoption of continuous and semi-continuous approach is likely to enable the net, annual cost savings of close to USD 50 billion.

By 2030, the opportunity within the continuous and semi-continuous bioprocessing market is likely to be over USD 500 million
Presently, the use of continuous and semi-continuous bio-intensification approach is largely restricted to the developed nations, and the majority of revenues from biologics manufactured via this approach are distributed between North America (~25%) and Europe (~40%). Once this process is adopted for the end-to-end manufacturing of biologics, estimates in the report suggest are likely to grow at even higher pace.

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/continuous-and-semi-continuous-bioprocessing-market/request-sample.html

Key Questions Answered

• Who are the leading contract manufacturers with expertise in continuous and semi-continuous bioprocessing?
• Who are the leading innovators / drug developers with expertise in continuous and semi-continuous bioprocessing?
• In which regions are majority of the continuous and semi-continuous bioprocessing facilities located?
• What is the likely cost saving potential of continuous and semi-continuous bioprocessing technology?
• What is the currently installed global capacity for continuous and semi-continuous bioprocessing?
• How is the current and future market opportunity likely to be distributed across key market segments?

The USD 500+ million (by 2030) financial opportunity associated with continuous and semi-continuous bioprocessing services market has been analyzed across the following segments:

• Type of Manufacturer
  • Innovator / Drug Developer
  • Contract Service Provider
• Company Size
  • Large
  • Mid-sized
  • Small
• Scale of Operation
  • Preclinical / Clinical
  • Commercial 
• Stage of Bioprocess
  • Upstream Bioprocessing
  • Downstream Bioprocessing
• Geographical Regions
  • North America
  • Europe
  • Asia-Pacific
  • MENA
  • Latin America and Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom, continuous and semi-continuous bioprocessing technologies are likely to witness a significant increase in the adoption rate in the near future, given their advantages over the traditional bioprocessing technologies. The report includes detailed transcripts of discussions held with the following experts:

• Jon Coffman (Senior Director of Bioprocess Technology and Engineering, AstraZeneca) 
• Ehsan Mahdinia (Assistant Professor, Albany College of Pharmacy and Health Sciences)
• Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences)

The research includes profiles of key players (listed below), featuring a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.

• AGC Biologics
• Biogen
• Bristol-Myers Squibb
• Enzene Biosciences
• FUJIFLM Diosynth Biotechnologies 
• Merck KGaA
• Novasep
• Sanofi Genzyme
• UCB Pharma
• WuXi Biologics

For additional details, please email at sales@rootsanalysis.com

Contact:
Gaurav Chaudhary
Gaurav.chaudhary@rootsanalysis.com